Latest Content

When researchers excluded studies that did not use proper methods to collect data, the results showed no connection between the medication and genetic disorder.

Shionogi and GSK are streamlining ViiV Healthcare’s ownership by buying out Pfizer’s 11.7% stake, leaving the HIV specialist jointly owned by its two long-time partners.

The AI dilemma facing biopharma—and what’s at risk.

A comparison of 2024 and 2025 bio/pharma employment survey results indicates that industry professionals face eroding security, polarized satisfaction, and rising attrition risk.

GSK is strengthening its allergy and immunology pipeline with a $2.2 billion acquisition of RAPT Therapeutics which includes ozureprubart, a long-acting, potentially best-in-class anti-IgE antibody.

In today’s Pharmaceutical Executive Daily, Henlius enters a global exclusive licensing agreement with UMAb Biopharma for a potential best-in-class anti-IL-1RAP antibody, a new report highlights drugmakers raising list prices amid pricing agreements with the Trump administration, and Novartis urges governments to address mounting global trade policy challenges impacting the biopharmaceutical industry.

Atkins is leveraging a partnership with reality TV star Heather Gay and early clinical trial data to reposition nutrition as a critical, science-backed complement to GLP-1 weight-loss therapies.

The biggest and most important takeaways from the recent JP Morgan Healthcare Conference.

Shanghai Henlius used the 2026 J.P. Morgan Healthcare Conference to announce an exclusive global license for a potentially best-in-class anti-IL-1RAP monoclonal antibody that expands the company beyond oncology into high-unmet-need autoimmune and inflammatory diseases.

Despite pledges to lower drug costs through Trump-backed pricing deals and direct-to-patient programs, pharmaceutical companies entered 2026 by raising list prices on hundreds of brand-name medicines, underscoring the limited impact of recent policy efforts on the broader U.S. drug pricing landscape.

Ken Keller, Daiichi Sankyo’s head of global oncology and CEO of US operations, discusses the importance of bringing quality data to the JP Morgan Healthcare Conference.

The company composed a letter addressed to global governments to harness competitiveness and innovation to navigate the current global trade economy.

Daiichi Sankyo’s US CEO and head of global oncology Ken Keller explains what his expectations are for JP Morgan prior to the conference.